These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 32101882)

  • 1. Effectiveness of Switching to Darunavir/Cobicistat in Virologically Suppressed HIV-Positive Patients Receiving Ritonavir-Boosted Protease Inhibitor-Based Regimen: The "STORE" Study.
    Gori A; Antinori A; Vergori A; Cossu MV; Menzaghi B; Sterrantino G; Rusconi S; Cattelan AM; Castelli F; Gianotti N; Orofino G; Ripamonti D; Savinelli S; Manzillo E; Santantonio TA; Celesia BM; Cauda R; Maserati R; d'Arminio Monforte A; Stingone C; Bonora S; Uglietti A; Termini R; Rucci F; Mancusi D
    J Acquir Immune Defic Syndr; 2020 Jul; 84(3):290-294. PubMed ID: 32101882
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Simplification of Antiretroviral Treatment from Darunavir/Ritonavir Monotherapy to Darunavir/Cobicistat Monotherapy: Effectiveness and Safety in Routine Clinical Practice.
    Santos JR; Curran A; Navarro-Mercade J; Ampuero MF; Pelaez P; Pérez-Alvarez N; Clotet B; Paredes R; Moltó J
    AIDS Res Hum Retroviruses; 2019 Jun; 35(6):513-518. PubMed ID: 30909716
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Analysis of virological response to therapy and resistance profile in treatment-experienced and naive HIV-1 infected Romanian patients receiving regimens containing darunavir boosted with ritonavir or cobicistat.
    Marin RC; Streinu-Cercel A; Moleriu LC; Bungau SG
    Biomed Pharmacother; 2022 Jun; 150():113077. PubMed ID: 35658217
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Darunavir/cobicistat showing similar effectiveness as darunavir/ritonavir monotherapy despite lower trough concentrations.
    Gutierrez-Valencia A; Trujillo-Rodriguez M; Fernandez-Magdaleno T; Espinosa N; Viciana P; López-Cortés LF
    J Int AIDS Soc; 2018 Feb; 21(2):. PubMed ID: 29430854
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Simplification to coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus continuation of ritonavir-boosted protease inhibitor with emtricitabine and tenofovir in adults with virologically suppressed HIV (STRATEGY-PI): 48 week results of a randomised, open-label, phase 3b, non-inferiority trial.
    Arribas JR; Pialoux G; Gathe J; Di Perri G; Reynes J; Tebas P; Nguyen T; Ebrahimi R; White K; Piontkowsky D
    Lancet Infect Dis; 2014 Jul; 14(7):581-9. PubMed ID: 24908551
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dual Raltegravir-Darunavir/Ritonavir Combination in Virologically Suppressed HIV-1-Infected Patients on Antiretroviral Therapy Including a Ritonavir-Boosted Protease Inhibitor Plus Two Nucleoside/Nucleotide Reverse Transcriptase Inhibitors.
    Calza L; Danese I; Magistrelli E; Colangeli V; Manfredi R; Bon I; Re MC; Conti M; Viale P
    HIV Clin Trials; 2016 Feb; 17(1):38-47. PubMed ID: 26728706
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of switching from boosted protease inhibitors plus emtricitabine and tenofovir disoproxil fumarate regimens to single-tablet darunavir, cobicistat, emtricitabine, and tenofovir alafenamide at 48 weeks in adults with virologically suppressed HIV-1 (EMERALD): a phase 3, randomised, non-inferiority trial.
    Orkin C; Molina JM; Negredo E; Arribas JR; Gathe J; Eron JJ; Van Landuyt E; Lathouwers E; Hufkens V; Petrovic R; Vanveggel S; Opsomer M;
    Lancet HIV; 2018 Jan; 5(1):e23-e34. PubMed ID: 28993180
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HIV treatment simplification to elvitegravir/cobicistat/emtricitabine/tenofovir disproxil fumarate (E/C/F/TDF) plus darunavir: a pharmacokinetic study.
    Harris M; Ganase B; Watson B; Harrigan PR; Montaner JSG; Hull MW
    AIDS Res Ther; 2017 Nov; 14(1):59. PubMed ID: 29096670
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Darunavir/cobicistat/emtricitabine/tenofovir alafenamide in treatment-experienced, virologically suppressed patients with HIV-1: subgroup analyses of the phase 3 EMERALD study.
    Huhn GD; Eron JJ; Girard PM; Orkin C; Molina JM; DeJesus E; Petrovic R; Luo D; Van Landuyt E; Lathouwers E; Nettles RE; Brown K; Wong EY
    AIDS Res Ther; 2019 Aug; 16(1):23. PubMed ID: 31464642
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Week 96 efficacy and safety results of the phase 3, randomized EMERALD trial to evaluate switching from boosted-protease inhibitors plus emtricitabine/tenofovir disoproxil fumarate regimens to the once daily, single-tablet regimen of darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) in treatment-experienced, virologically-suppressed adults living with HIV-1.
    Eron JJ; Orkin C; Cunningham D; Pulido F; Post FA; De Wit S; Lathouwers E; Hufkens V; Jezorwski J; Petrovic R; Brown K; Van Landuyt E; Opsomer M;
    Antiviral Res; 2019 Oct; 170():104543. PubMed ID: 31279073
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Simplification from twice-daily to once-daily darunavir/ritonavir in a randomized trial among HIV-infected persons with HIV-1 RNA suppression on antiretroviral therapy.
    Huhn GD; Sigman A; Livak B
    Antivir Ther; 2015; 20(8):849-54. PubMed ID: 25881614
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Darunavir/cobicistat maintains the effectiveness of darunavir/ritonavir in HIV-infected patients under mono or dual therapy.
    Mena Á; Cid P; Dueñas C; Garcinuño MÁ; Lorenzo JF; Margusino L; Quiñones M; Grande C; Rodríguez-Osorio I; Castro Á
    HIV Clin Trials; 2018 Oct; 19(5):197-201. PubMed ID: 30605006
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Significant improvement in triglyceride levels after switching from ritonavir to cobicistat in suppressed HIV-1-infected subjects with dyslipidaemia.
    Echeverría P; Bonjoch A; Puig J; Ornella A; Clotet B; Negredo E
    HIV Med; 2017 Nov; 18(10):782-786. PubMed ID: 28671337
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lack of impact of protease inhibitor resistance-associated mutations on the outcome of HIV-1-infected patients switching to darunavir-based dual therapy.
    Vizcarra P; Blanco JL; Montejano R; Negredo E; Espinosa N; Casado JL;
    Infect Dis (Lond); 2020 Mar; 52(3):202-206. PubMed ID: 31760833
    [No Abstract]   [Full Text] [Related]  

  • 15. Darunavir concentrations in CSF of HIV-infected individuals when boosted with cobicistat versus ritonavir.
    Bartels H; Decosterd L; Battegay M; Marzolini C
    J Antimicrob Chemother; 2017 Sep; 72(9):2574-2577. PubMed ID: 28575323
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Virological outcomes and metabolic effects after switching from ritonavir-boosted protease inhibitors to a dolutegravir-based regimen in virologically suppressed patients living with HIV.
    Sribenjalux W; Nuntawit T; Meesing A; Chetchotisakd P
    Int J STD AIDS; 2023 Feb; 34(2):98-107. PubMed ID: 36378013
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Darunavir/cobicistat monotherapy. Experience in a tertiary hospital].
    Yunquera-Romero L; Asensi-Díez R; Del Rio-Valencia JC; Muñoz-Castillo I; Castaño-Carracedo MA
    Rev Esp Quimioter; 2016 Dec; 29(6):308-317. PubMed ID: 27888600
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dual Therapy With Darunavir and Ritonavir Plus Lamivudine vs Triple Therapy With Darunavir and Ritonavir Plus Tenofovir Disoproxil Fumarate and Emtricitabine or Abacavir and Lamivudine for Maintenance of Human Immunodeficiency Virus Type 1 Viral Suppression: Randomized, Open-Label, Noninferiority DUAL-GESIDA 8014-RIS-EST45 Trial.
    Pulido F; Ribera E; Lagarde M; Pérez-Valero I; Palacios R; Iribarren JA; Payeras A; Domingo P; Sanz J; Cervero M; Curran A; Rodríguez-Gómez FJ; Téllez MJ; Ryan P; Barrufet P; Knobel H; Rivero A; Alejos B; Yllescas M; Arribas JR;
    Clin Infect Dis; 2017 Nov; 65(12):2112-2118. PubMed ID: 29020293
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Short Communication: Efficacy and Safety of Treatment Simplification to Lopinavir/Ritonavir or Darunavir/Ritonavir Monotherapy: A Randomized Clinical Trial.
    Santos JR; Llibre JM; Bravo I; García-Rosado D; Cañadas MP; Pérez-Álvarez N; Paredes R; Clotet B; Moltó J
    AIDS Res Hum Retroviruses; 2016 May; 32(5):452-5. PubMed ID: 26781004
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effectiveness, durability, and safety of darunavir/ritonavir in HIV-1-infected patients in routine clinical practice in Italy: a postauthorization noninterventional study.
    Antinori A; Meraviglia P; Monforte Ad; Castagna A; Mussini C; Bini T; Gianotti N; Rusconi S; Colella E; Airoldi G; Mancusi D; Termini R
    Drug Des Devel Ther; 2016; 10():1589-603. PubMed ID: 27226708
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.